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Varicella-zoster virus (VZV) is an alphaherpesvirus responsible for two human diseases: chicken pox 
and shingles. The virus has a respiratory port of entry. After two successive viremias, it reaches the 
skin where it causes typical lesions. There, it penetrates the peripheral nervous system and it remains 
latent in dorsal root ganglia. It is still debatable whether VZV persists in neurons or in satellite cells. 
During latency, VZV expresses a limited set of transcripts of its immediate early (IE) and early (E) 
genes but no protein has been detected. Mechanisms of reactivation from ganglia have not been 
identified. However, dysfunction of the cellular immune system appears to be involved in this process. 
The cell-associated nature of VZV has made it difficult to identify a temporal order of gene expression, 
but there appears to be a cascade mechanism as for HSV-1. The lack of high titre cell-free virions or 
recombination mutants has hindered so far the understanding of VZV gene functions. Five genes, 
ORFs 4, 10, 61, 62, and 63 that encode regulatory proteins could be involved in VZV latency. ORF4p 
activates gene promoters with basal activities. ORF10p seems to activate the ORF 62 promoter. 
ORF61p has trans-activating and trans-repressing activities. The major IE protein ORF62p, a virion 
component, has DNA-binding and regulatory functions, transactivates many VZV promoters and even 
regulates its own expression. ORF63p is a nuclear IE protein of yet unclear regulatory functions, 
abundantly expressed very early in infection. We have established an animal model of VZV latency in 
the rat nervous system, enabling us to study the expression of viral mRNA and protein expression 
during latency, and yielding results similar to those found in humans. This model is 
beginning to shed light on the molecular events in VZV persistent infection and on the regulator 
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1. The virus and its replication 
 
Varicella-zoster virus (VZV), belongs to the Herpesviridae family. It is closely related to other 
herpesviruses such as herpes simplex viruses (HSV-1 and HSV-2), cytomegalovirus (CMV) and 
Epstein-Barr virus (EBV), human herpesviruses 6 and 7 (HHV-6 and -7) as well as numerous animal 
herpesviruses (BHV-1, -2, -5, EHV-1, CapHV-1, CerHV-1, -2 and PRV). VZV belongs to the 
Alphaherpesvirinae subfamily like HSV-1 and -2 in human, suid herpesvirus 1 in swine (also known as 
pseudorabies virus, PRV) and bovine herpesvirus 1 (BHV-1) in cattle. They all share important 
characteristics, such as neurotropism, a rapid and highly lytic replicative cycle as well as the ability to 
undergo latency, particularly in the peripheral and, to a lesser extent, central nervous system and to 
reactivate. 
Specifically human in its host range, VZV is responsible for one of the best recognized persistent viral 
infections in man. However, the molecular mechanisms controlling its latency in the nervous system 
and its reactivation remain unclear. VZV was first isolated in cultures of human embryonic fibroblasts 
by T.H. Weller (Weller and Stoddard, 1952; Weller, 1953), who also demonstrated that the agent 
responsible for chicken pox and shingles was one and the same (Weller et al., 1958). As revealed by 
electron microscopy, VZV cannot be distinguished from other herpesviruses. It is an enveloped virus, 
180 to 200 nm in diameter, which does not bud at the plasma membrane of the infected cell, but at the 
internal membrane of the nucleus. Its capsid is icosahedral and encloses a double-stranded linear DNA 
wrapped around a protein structure. The space between the capsid and the envelope is filled with a 
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tegument, the protein(s) of which could play a major role in the immediate triggering of viral 
transcription when the virus enters its target cell, by analogy with the role of α-TIF in HSV-1. 
The viral DNA has been cloned and fully sequenced (Davison and Scott, 1986). It contains 124,884 
base pairs. The genome reveals 71 open reading frames, coding for 67 proteins, of which only about 
one half have been identified. 
The replicative cycle of VZV is classical for herpesviruses. The virus adsorbs onto target cells through 
specific receptors yet undetermined, although the mannose 6-phos-phate receptor and heparan sulfate 
could play an important role (Zhu et al., 1995). The capsid penetrates into the cell and releases the viral 
genome which travels to the nucleus. The cell transcribes the immediate early genes (IE), then the early 
genes (E). Corresponding transcripts are translated into proteins that control viral genome replication 
and transcription of late genes (L) coding for virus structural proteins and some non-structural proteins 
which will remain in the cell. The late stage of viral replication is virion assembly. Structural proteins 
synthesized in the cytoplasm migrate to the nucleus, assemble into capsomers then in complete capsids 
enclosing the viral DNA. 
 
 
2.  Chicken pox 
 
The virus penetrates by the upper respiratory tract and infects the respiratory mucosa where it 
multiplies. After 4 to 6 days, the virus disseminates in the bloodstream. This primary viremia allows 
the virus to infect reticulo-endothelial cells. Several multiplication cycles occur there during the 
incubation period. A second viremia, more widespread, occurs one week later. Prodromal signs appear, 
then cutaneous and mucous lesions on day 14. The virus also infects other organs such as the gastro-
intestinal and genitourinary tracts, pleural and peritoneal membranes as well as parenchyma of nearly 
all organs. This secondary viremia ends after 3 days with the help of the immune system (Hope-
Simpson, 1965). Muscular and articular pain may precede the onset of the rash, usually accompanied 
by fever. Vesicles, the fluid of which is extremely rich in infectious virus, are visible during 4 days, 
then scab after 2 to 3 days. 
Chicken pox is usually followed by a latent infection of the peripheral nervous system ganglia where 
the virus can reactivate many years later and provoke shingles (Hope-Simpson, 1965). Zoster is thus 
the result of a viral reactivation from a ganglion and not from an exogenous reinfection. Virus was 
found in ganglia by electron microscopy and immunofluorescence (Eisiri and Tomlinson, 1972; 
Nagashima et al., 1975). Later, the presence of its genome was revealed by in situ hybridization 
(Gilden et al., 1983; Hyman et al., 1983; Vafai et al., 1988; Croen et al., 1988). However, the state of 
the latent genome and the mechanism of its reactivation remain elusive. If, in vitro, HSV is easily 
reactivated from latently infected sensory ganglia after explanation, such a reactivation has not been 
conclusively described for VZV. 
 
 
3.  Zoster-associated pain (ZAP) 
 
Very often, the zoster episode is accompanied by severe pain which can be prodromal and lasts usually 
a few days. Sometimes, mostly in elderly patients, pain can last much longer, from several weeks to 
several years. It is now generally considered that, although it is impossible for the patient to tell the 
difference, ZAP is composed of two distinct pains: the acute pain during the zoster episode and the 
persistent pain, called post-herpetic neuralgia (PHN). PHN, by far the most distressful aspect of VZV 
infection, occurs when the virus is apparently cleared. It could result from lesions made to neurons 
involved in pain or in the control of pain. 
 
 
4.  Animal models 
 
This lack of information concerning VZV latency and reactivation results mostly from the difficulty to 
set up a suitable animal model which would reproduce all the characteristics of VZV infection in 
humans. Although guinea pigs were often used to study VZV pathogenesis after inoculation of guinea-
pig-adapted infectious virus (Matsunaga et al., 1982; Myers et al., 1985; Walz-Cicconi et al., 1986; 
Myers et al., 1991), latency had not been demonstrated in these models until recently (Lowry et al., 
1993). The first models of VZV latency were described in the adult rat nervous system in vitro 
(Merville-Louis et al., 1989) and in vivo (Sadzot-Delvaux et al., 1990, 1995b). Other experimental 
models of latency, such as in mice (Wroblewska et al., 1993) or in rabbits (Dunkel et al., 1995) have 
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VZV is able to penetrate several cell types in vivo and it is not known whether the mechanism of cell 
recognition is the same for neurons and other cells. However, it is safe to assume that entry into nerve 
cells is mediated through the interaction between an external protein of the virion and a 'receptor' 
present at the surface of the target cell. Since Herpesviridae possess 7 or 8 surface glycoproteins (VZV 
has only 6) and several non-glycosylated transmembrane proteins, there are many candidates for such 
interactions. Neuron infection could also be conditioned in a later step of the infectious process, during 
penetration, uncoating or even later. A late gene of HSV-1 which is not necessary for growth in culture 
has been proposed as responsible for neurovirulence (Chou et al., 1990). Its equivalent in VZV should 
be looked for and, if it exists, it would thus be an interesting target for neurotropism knock out. Indeed, 
attenuation of VZV virulence such as in the current OKA vaccine strain does not prevent neurotropism. 
It would be useful to construct recombinant viruses lacking one or several proteins to identify those 
responsible for neurotropism. Such mutants have been developed for PRV and HSV. Because of the 
cell-associated nature of VZV, this approach has failed. However, there is now hope to achieve such a 
goal since infectious particles of VZV have been generated by transfection of human melanoma cells 
with overlapping cosmid clones (Cohen and Seidel, 1993). Moreover, the yield of infectious virus 
generated by this type of transfection was greatly improved (70 fold) when the purified VZV DNA was 
cotransfected with a plasmid expressing IE62 (Moriuchi et al., 1994a). This approach could become 
essential in the near future for generating recombinant VZV virions and for engineering non- 
neurotropic vaccine strains. 
In HSV latency, it has been demonstrated that the virus remains quiescent in sensory ganglia neurons. 
The search for VZV components in human ganglia yielded contradictory information about the cell 
type in which the virus resides during latency: studies indicated the presence of viral nucleic acids 
exclusively in neurons (Hyman et al., 1983; Gilden et al., 1987) while in another set of experiments, 
viral-specific RNAs were found in non-neuronal cells surrounding the neuron (Croen et al., 1988; 
Croen and Straus, 1991; Meier and Straus, 1992). In the latter case, the hypothesis is that the virus 
remaining quiescent in non-neuronal cells is reactivated in these cells and infects other satellite cells 
before reaching the neurons. This is consistent with the comparative pathogenesis of herpes zoster and 
herpes simplex recurrences. In zoster, the virus would spread from neuron to neuron within a ganglion 
by replicating in the satellite cells and travel back to the skin along numerous axons, causing 
widespread lesions in the skin of an entire dermatome. In herpes simplex, the virus residing in a neuron 
would become reactivated in that neuron and travel back to the skin along one axon, causing focalized 
lesions in the skin (Meier and Straus, 1992). 
In the in vivo model of latency that we have established in the rat (Sadzot-Delvaux et al., 1990, 1995b), 
we could detect VZV antigens and nucleic acids after dissociation and culture of DRG cells. In these 
conditions, localization was neuron-specific. However, in DRG sections, viral nucleic acids could be 
detected both in neuronal and non-neuronal cells. These data were obtained after a short time of 
infection (7 days) and they can reflect the early events of latency during which virus could infect 
different cell types productively before becoming quiescent. No reactivation could be observed in this 
system, except by explanation, repeated trypsinizations and cocultures with permissive cells. 
 
 
6. Viral gene regulation 
 
Unraveling the regulation of gene expression could be essential to understand the neurotropism and 
latency of VZV. In particular, the regulation of the very early steps of the viral cycle could be different 
during lytic or latent infection. Many studies have demonstrated that viral IE and E genes are 
transcribed during VZV latency. It seems that, in nerve cells, viral gene regulation is abnormal and 
progress of infection is modified or even impaired. 
Five VZV genes encoding proteins with regulatory functions could be involved in the establishment 
and maintenance of virus latency in ganglia: open reading frames (ORFs) 4, 10, 61, 62 and 63. 
 
 
6.1. ORF 4 
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VZV ORF 4 encodes a protein (ORF4p) exhibiting both structural and transcriptional regulatory 
functions and possibly present in the virus particle (Kinchington et al., 1995). ORF4p shares 
considerable amino acid sequence similarity with HSV-1 ICP27 and EHV-1 UL3. ORF 4 is transcribed 
as two mRNAs (1.8 and 3.0 kb) with a single initiation site (Kinchington et al., 1994). Although ICP27 
is essential for HSV-1 replication, the role of ORF4p is not well understood. Both have distinct 
regulatory properties in vitro (Inchauspe et al., 1989; Inchauspe and Ostrove, 1989; Defechereux et al., 
1993) and they are unable to complement each other efficiently (Moriuchi et al., 1994b). ORF4p can 
activate several VZV genes on its own or in combination with ORF62p but it has no repressing 
activity. In fact it appears to be able to activate VZV as well as heterologous viral promoters providing 
they have a basal activity. Heterologous regulation by ORF4p seems to be transcriptional, but its 
regulation of VZV promoters could be post-transcriptional (Defechereux et al., 1993). As opposed to 
ICP27, ORF4p activates various promoters if they display upstream elements which mediate its 
transcriptional effects and this activity involves the cysteine-rich C-terminus of ORF4p (Perera et al., 
1994) while the N-terminal domain of ICP27 and ORF4p are functional homologs (Moriuchi et al., 
1995). Viral infection is amplified when ORF4p is expressed in cells transfected with ORF4 
(Schoonbroodt et al., 1996). 
 
 
6.2.  ORF 10 
 
The ORF 10-encoded protein (ORF10p), like its homolog HSV-1 VP16, is part of the virion tegument. 
However, its functions are not clearly identified. ORF10p is 80 amino acids shorter than VP16 at the C-
terminus. Its promoter is very weak (Moriuchi et al., 1993). Even though ORF10p neither complexes 
with a TAATGARAT element nor with cellular proteins as opposed to VP16 (McKee et al., 1990), it 
trans-activates ORF 62 and HSV-1 ICP4 (Moriuchi et al., 1993). ORF10p-expressing cell lines can 
complement a HSV-1 VP16 mutant lacking trans-activating functions. ORF10p enhances virus 
productivity in these cells when transfected with HSV-1 virion DNA (Moriuchi et al., 1993). While 
HSV VP16 is essential for immediate trans-activation of HSV genes, VZV ORF1Op is dispensable for 
VZV replication in vitro (Cohen and Seidel, 1994). 
 
 
6.3.  ORF 61 
 
The ORF 61 encoded protein (ORF61p) shares a limited amino acid sequence similarity with HSV-1 
ICPO which functions as a transcriptional activator. ORF61p is present in VZV-infected cell nuclei as 
a heterogeneous protein phosphorylated at the N-terminal region (Stevenson et al., 1992), which 
contains a RING finger domain required for its transregulatory functions (Moriuchi et al., 1994c). 
Phosphorylation is weaker at the C-terminal region which directs transport of ORF61p to the nucleus 
(Stevenson et al., 1992). The regulatory functions of ORF61p are still controversial. It could repress the 
activity of VZV-encoded trans-activators of putative viral IE (ORF 62 and 4), E (TK), and L (gE) gene 
promoters, at the transcriptional level (Nagpal and Ostrove, 1991; Moriuchi et al., 1992). However, 
neither trans-activating nor trans-repressing activities were observed in T lymphocyte lines unless 
ORF61p acts in combination with ORF62p and synergizes the activation of ORF 4, ORF 61 and TK 
gene promoters (Perera et al., 1992a). 
 
 
6.4.  ORF 62 
 
The ORF 62 gene product (ORF62p) is the major VZV regulatory protein and it is expressed as a 
nuclear IE phosphoprotein (Shiraki and Hyman, 1987). It can complement HSV ICP4-mutants of HSV-
1 and it is thus a functional analog of ICP4 (Felser et al., 1988; Disney and Everett, 1990). Indeed, 
there is a large amino acid similarity (McGeoch et al., 1986; Ostrove, 1990; Davison, 1991). ORF62p 
is present in large amounts in the virus tegument (Kinchington et al., 1992). It transactivates VZV gene 
promoters of all classes strongly and in a dose-dependent fashion and it must play a crucial role in the 
replication of VZV (Inchauspe et al., 1989; Inchauspe and Ostrove, 1989; Perera et al., 1992a,b). It can 
also either repress or activate its own promoter depending on its concentration (Disney et al., 1990; 
Perera et al., 1992b; Baudoux et al., 1995). Viral infection is boosted when ORF62p is expressed in 
cells transfected with ORF62 (Schoonbroodt et al., 1996). ORF62p has distinct functional domains: a 
powerful activation domain in the N-terminal region (Perera et al., 1993; Cohen et al., 1993), a domain 
at the border between regions 4 and 5 playing possibly a role in promoter activation and repression 
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(Baudoux et al., 1995), a DNA-binding domain in region 2 (Wu and Wilcox, 1991; Tyler and Everett, 
1993; Tyler et al., 1994) and a nuclear localization signal in region 3 (Baudoux et al., 1995). ORF62p 
activates the DNA polymerase and the major DNA binding protein genes of VZV (ORFs 28 and 29), 
which are juxtaposed in the genome (Meier et al., 1994). This is done bidirectionally in cooperation 




6.5. ORF 63 
 
The ORF 63-encoded protein, ORF63p, is associated with the virion (Kinchington et al., 1995). As a 
true IE protein, it is found in infected cell nuclei as early as 6 h after infection (Debrus et al., 1995), 
later in the cytoplasm. Two mRNAs are transcribed from ORF 63 (1.3 and 1.9 kb) and multiple 
transcription start sites have been identified but, unlike in HSV-1 IE genes, no TAATGARAT motif 
(Kinchington et al., 1995). Regulatory functions of ORF63p are not yet defined. It activates the VZV 
TK gene (ORF 36) promoter (Jackers et al., 1992), but none other (Kost et al., 1995). We found 
recently that ORF63p reduces the activating effect of ORF4p on the ORF 62 promoter (S. Debrus, 
unpublished). ORF63p is heavily expressed in rat dorsal root ganglia neurons during latency as well as 
in the skin of patients with early herpes zoster symptoms (Debrus et al., 1995). The role of ORF63p in 
latency or/and reactivation could thus be important and it is worth being further investigated. 
All the information mentioned above is based upon data collected in transient expression experiments 
in vitro. The situation must be much more complicated in cells where the various regulatory proteins 
interact with each other. 
 
 
7. Latency and reactivation 
 
Contrary to other Alphaherpesvirinae, VZV latency is not characterized by the presence of a latency-
associated transcript (LAT). Large regions of the genome are transcribed (for review, see Ref. Hay and 
Ruyechan, 1994), but the virus has never been reactivated ex vivo by plating the ganglia in culture. 
Mechanisms triggering reactivation in vivo are still unknown. In man, reactivation goes along with 
immunosuppression or immune dysfunction (Hata, 1980). However, the link between these phenomena 
is still largely hypothetical. 
Transcripts of ORF 4, ORF 29, ORF 62 and ORF 63 have been found in ganglia of human cadavers 
with no sign of VZV reactivation at the time of death (Croen et al, 1988; Croen and Straus, 1991; 
Meier et al., 1993). In our rat model of VZV latency, we have also found by PCR the expression of 
ORF 4, ORF 29, ORF 62 and ORF 63 transcripts and in addition, we could detect ORF63p with an 
antiserum raised against a recombinant ORF63p expressed in procaryotes (Sadzot-Delvaux et al., 
1995b; Debrus et al., 1995). Others have reported the detection in humans, by PCR, of the expression 
of ORF 21 and possibly ORF 10, two putative late genes (Cohrs et al., 1992, 1994). The reason for this 
discrepancy is not clear. It could be related to the delay before processing the samples post mortem, 
with a possible at least partial reactivation of the virus at the time of death. 
ORFs 4, 62 and 63 are IE genes while ORF 29 is an E gene. Their expression during latency stresses 
the potential importance of these sequences and of the proteins they code for in the maintenance of 
latency, perhaps in its establishment as well, and in reactivation. 
Several scenari can be proposed to explain VZV latency: 
1.  neurons could generate a specific factor interacting with transcription or repressing viral expression; 
2.  neurons could fail to generate a specific factor needed to complete the viral cycle; 
3.  a factor generated outside the neurons could repress viral transcription in neurons; 
4.  a Bel 2-like molecule could protect nerve cells from VZV-induced apoptosis. 
This latter hypothesis is based on our observations that VZV induces apoptosis in infected cells and 
that the first cytopathic effect seen in VZV-infected cells is apoptotic. By preventing apoptosis, the 
neurons could in fact induce virus latency. However, the anti-apoptosis factor in this case is not the 
well-known proto-oncogene Bel 2 since VZV-induced apoptosis is not Bel 2-sensitive (Sadzot-Delvaux 
et al., 1995a). 
Another hypothesis based on antibody-induced latency by antigenic modulation, as for other enveloped 
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Although it is difficult to find in what respect the studies on VZV could teach any lesson to those 
studying herpesviruses of veterinary importance, a few take-home messages can be delineated. 
The virus grows very poorly in culture. The first lesson is thus patience and obstinacy. There is still no 
complete animal model covering primary and secondary infection, neurotropism, latency and 
reactivation, rash and pain. These difficulties hamper considerably the advance of knowledge on VZV 
and its persistence. Indirect approaches had to be used through cloning and sequencing, genome and 
transcript probing, expression of recombinant proteins and peptide synthesis to generate specific 
antibodies. Neurotropism can now be monitored in an animal model (rat), raising hopes that one or 
several proteins will be identified as involved in virus access to the nervous system and consequently 
as targets for gene knock out manipulations in order to engineer new generation vaccines. Investigation 
has moved ahead in a manageable field: in vitro assessment of gene regulation, beginning to uncover 
the intimate mechanisms controlling virus replication. This new knowledge will lead hopefully to the 
design of drugs effective on these virus-specific pathways. Finally, the use of cosmid cloning will make 
it possible to work with infectious DNA and open the way for efficient large scale site-specific 
mutagenesis. 
Finally, the most important lesson is probably to refrain from building HSV into an archetype for 
Alphaherpesvirinae. HSV-1 is certainly the most studied virus of the group, in part because it grows 
easily and abundantly in culture and because animal models have been available for a long time. 
However, it is becoming clear that not only its neurotropism, its latency and its reactivation are 
different, but also its molecular regulation. Extrapolating HSV data directly to other members of the 
subfamily, as we all tend to do at first, could be grossly misleading. Each virus should be studied for 
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